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Abstract
Background: Laparoscopic radical cystectomy (LRC) and robot-assisted radical cystec-
tomy (RARC) are increasingly popular, but high-level evidence for these techniques
remains lacking.
Objective: To compare the outcomes of patients undergoing open radical cystectomy
(ORC), RARC, and LRC.
Design, setting, and participants: From March 2009 to July 2012, 164 patients requiring
radical cystectomy for muscle-invasive bladder cancer or high-risk non–muscle-invasive
bladder cancer were invited to participate, with an aim of recruiting 47 patients into each
arm. Overall, 93 were suitable for trial inclusion; 60 (65%) agreed and 33 (35%) declined.
Intervention: ORC, RARC, or LRC with extracorporeal urinary diversion.
Outcome measurements and statistical analysis: Primary end points were 30- and 90-d
complication rates. Secondary end points were perioperative clinical, pathologic, and
oncologic outcomes, and quality of life (QoL). The Fisher exact test and analysis of
variance were used for statistical analyses.
Results and limitations: The 30-d complication rates (classiﬁed by the Clavien-Dindo
system) varied signiﬁcantly between the three arms (ORC: 70%; RARC: 55%; LRC: 26%;
p = 0.024). ORC complication rates were signiﬁcantly higher than LRC (p < 0.01). The 90-
d complication rates did not differ signiﬁcantly between the three arms (ORC: 70%;
RARC: 55%; LRC 32%; p = 0.068). Mean operative time was signiﬁcantly longer in RARC
compared with ORC or LRC. ORC resulted in a slower return to oral solids than RARC or
LRC. There were no signiﬁcant differences in QoL measures. Major limitations are the
small sample size and potential surgeon bias.
Conclusions: The 30-d complication rates varied by type of surgery and were signiﬁ-
cantly higher in the ORC arm than the LRC arm. There was no signiﬁcant difference in
90-d Clavien-graded complication rates between the three arms.
Patient summary: We compared patients having open, robotic, or laparoscopic bladder
removal surgery for bladder cancer and found no difference in Clavien-graded compli-
cation rates at 90 d.
# 2015 Published by Elsevier B.V. on behalf of European Association of Urology.
* Corresponding author. Department of Urology, Guy’s and St. Thomas’ NHS Foundation Trust,
London, UK SE1 9RT.
E-mail address: shamim.khan@gstt.nhs.uk (M.S. Khan).
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1. Introduction
Until 1995, open radical cystectomy (ORC) was the only
surgical approach available in the management of muscle-
invasive bladder cancer (MIBC) or high-risk non–muscle-
invasive bladder cancer (NMIBC) [1,2]. ORC is associated
with high morbidity and significant mortality but remains
the gold standard [3]. Two minimally invasive surgical
approaches, laparoscopic radical cystectomy (LRC) and
robot-assisted radical cystectomy (RARC), have become
available in recent years, with the perceived advantage of
reduced morbidity and faster convalescence [4]. Although
many institutions have purchased surgical robots, they are
expensive, and in many parts of the world, laparoscopic
surgery still prevails as an alternative to open surgery
[5]. Although a few trials have compared ORC and RARC
[6–8], currently none have compared all three modalities.
2. Patients and methods
2.1. Hypothesis, study design, and patients
The Cystectomy Open Robotic and Laparoscopic (CORAL) trial is a
randomised controlled study comparing ORC, LRC, and RARC from March
2009 to July 2012, conducted at Guy’s Hospital, London, UK. Our
hypothesis was that the greater precision offered by robotic technology
would reduce complication rates for RARC compared with ORC and LRC.
All patients aged between 18 and 80 yr requiring radical cystectomy
(RC) for MIBC or high-risk NMIBC were invited to participate. Trial
inclusion did not affect diversion type or eligibility for neoadjuvant
chemotherapy. Patients were excluded from randomisation if deemed
unsuitable for LRC or RARC due to severe cardiorespiratory comorbidities
or extensive abdominopelvic surgery or radiation. Eligible patients were
counselled by a trial nurse (J.W.) and gave informed consent.
The study was prospectively registered with the Guy’s and
St. Thomas’s research and development ofﬁce (RJ109/0375) after
National Health Service Research Ethics Committee approval (08/
H0804/135), and retrospectively registered with the International
Standard Randomised Controlled Trial Number (ISRCTN) registry
(ISRCTN28499748; http://www.isrctn.com/ISRCTN28499748).
2.2. Randomisation
Randomisation was undertaken by the trial nurse (J.W.) using identical
sealed opaque envelopes, each containing a piece of paper designating
the surgical modality (ORC, LRC, or RARC). Simple randomisation was
performed in two groups of 30. In each group, each modality was
allocated 10 envelopes. These were shufﬂed and then numbered 1–30.
Patients received the next envelope in numerical order. Envelopes were
kept in a locked room, accessed only by the trial nurse to minimise
opportunities for tampering, and they were opened by the patient in the
presence of three members of the research team to ensure that no
changes were made to allocation. This study was nonblinded because the
different incisions would be difﬁcult to camouﬂage.
2.3. Interventions
Our technique of RARC was previously reported [9]; ORC and LRC
techniques are detailed in Supplement 1. Urinary diversion was
performed extracorporeally for all RARC and LRC cases, and all
neobladders were fashioned using the Studer technique [10]. Lymph
node dissection templates were standardised including obturator,
external/internal/common iliac, and presacral nodes. Lymph nodes
were not analysed in separate packets [11]. Three expert surgeons
performed ORC (M.S.K.), LRC (P.R.), and RARC (P.D.). At trial initiation,
M.S.K. had performed >150 ORCs, and P.R. and P.D. had performed about
110 LRCs and RARCs, respectively.
2.4. Postoperative management and follow-up
All patients underwent a standardised Enhanced Recovery Pathway for
RC [12]. After discharge, patients were reviewed at 2 wk, 3, 6, and 12 mo,
and then yearly. Following local protocol, loopogram studies were
performed at 3 mo to assess for ureteroenteric anastomotic strictures.
Chest, abdomen, and pelvis computed tomography scans were
performed at 6 and 12 mo for recurrence and other complications.
2.5. Outcome measures
Primary end points were 30- and 90-d complication rates classiﬁed by
Clavien-Dindo grades [13]. Secondary end points were perioperative
parameters (operative time, estimated blood loss [EBL], delay in bowel
function, and length of hospital stay [LOS]), pathologic outcomes
(margin status and number of lymph nodes retrieved), 12-mo oncologic
outcomes, and quality of life (QoL).
2.6. Quality of life
QoL was assessed by the Functional Assessment of Cancer Therapy-
Bladder (FACT-Bl) scale v.4 [14], covering physical well-being, functional
well-being, emotional well-being, social/family well-being, and additional
questions speciﬁc to bladder cancer (BCa; Bladder Cancer Subscale).
2.7. Power calculations and statistical analysis
Based on early experience, we estimated the RARC complication rate as
10–15% [15] and that for ORC as 25–60% [16]. Therefore, the number
needed in each arm ranges from 43 to 58 so the 95% conﬁdence interval
(CI) for the estimated difference in rates is 16%. Based on these
considerations, we aimed to recruit 47 patients per arm (based on the range
of complication rates). However, a 3-yr interim analysis suggested no
signiﬁcant difference in primary outcomes between arms, and coupled with
recruitment difﬁculties, our institutional research project steering board
recommended terminating the trial at this point.
Binary outcomes were compared using the Fisher exact test. Analysis
of variance (ANOVA) including the baseline value where appropriate was
used to compare means of continuous outcome measures. If the
difference between groups was statistically signiﬁcant, post hoc analysis
was performed using the Fisher exact pairwise comparison, Mann-
Whitney U, or the Tukey honest signiﬁcant difference test. Where test
assumptions for ANOVA were not justiﬁed, the Kruskal-Wallis test was
used. Survival analysis using the log-rank test was conducted, and
Kaplan-Meier survival curves were constructed. Additional QoL analysis
included adjusting for age, sex, and urinary diversion [17].
Data analysis was performed using SPSS v.21 (IBM Corp, Armonk, NY,
USA). A two-sided p value <0.05 was considered signiﬁcant. Results were
analysed by intention to treat.
3. Results
A total of 164 patients with MIBC or high-risk NMIBC were
assessed for trial inclusion between 2009 and 2012. Of
93 eligible patients, 60 (65%) agreed to participate, and 33
(35%) declined. The reason for declining was most
commonly patient preference for a specific approach.
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One patient assigned to LRC was withdrawn after further
histologic review showed small cell BCa for which surgery
was inappropriate, leaving 59 patients in the trial. All
20 patients assigned to ORC received the intended
procedure. One patient assigned to RARC was converted
to ORC due to equipment failure. Of the 19 patients
allocated to LRC, 3 were converted to RARC because of
laparoscopic surgeon unavailability at short notice. One
patient was converted to ORC due to large tumour size. All
patients completed 90-d follow-up, and 97% completed a
12-mo follow-up (Fig. 1).
3.1. Patient demographics
There were no important differences in baseline character-
istics (Table 1), number receiving neoadjuvant chemother-
apy, preoperative stage distribution (NMIBC or MIBC),
diversion type, and final pathologic stage between the three
arms (Table 2).
3.2. Primary clinical end point
3.2.1. 30-d complications
Overall, 14 of 20 ORC patients (70%), 11 of 20 RARC patients
(55%), and 5 of 19 LRC patients (26%) had at least one 30-d
complication (any Clavien grade). The overall variability
between groups was statistically significant. In addition,
ORC versus LRC arms were significantly different (95% CI for
difference, 44% [15–72%]; p = 0.01). There were no statisti-
cally significant differences between surgical arm and 30-d
major complications (Clavien 3) (Table 3).
3.2.2. 90-d complications
No statistically significant differences were found between
surgical arm and rates of all or major 90-d complications.
Complications are further classified by Clavien grade and
system (Tables 4 and 5). Clavien grade 1 was significantly
different at 30 d (ORC: 8, RARC: 3, LRC: 1; p = 0.030). There
were no statistically significant differences between other
Clavien grades at 30 or 90 d.
Assessed fo r eligibility (n = 164) 
Excl ude d (n = 104)  
♦ No t meeting inclusion  criteria  (n = 71) 
♦ Declined  to pa rticipate ( n = 33) 
♦ Other reason s (n = 0) 
Analy sed  (n = 20) 
♦ Excluded from  analysi s of oncolo gic 
outcomes  at  12 mo (n = 1) (lost to follow-up  at 
12 mo )
♦ Lost  to follo w-up at  90 d (n = 0) 
♦ Los t to follo w-up at 12 mo (n = 1) 
♦ Discontin ued interventi on (n = 0)
Allocated to  ORC  (n = 20) 
♦ Received allocated  intervention (n = 20)
♦ Did not re ceive alloca ted intervention (n  = 0)
♦ Lost  to  follo w-up at 90 d (n = 0) 
♦ Lost to follow-up  at  12 mo (n = 0) 
♦ Di scontinued  interv ention (n = 0)
Allocate d to RARC  (n = 20) 
♦ Received allo cated intervention (n = 19)
♦ Did  not receiv e allocated  inte rventi on (n = 1) 
(n = 1:  equipme nt fail ure: co nvert ed to  
ORC).
Analysed (n = 20) 
Allocati on
Analysis 
Follow-up
Rando mised (n = 60) 
Enrollment
Allocated to LRC ( n = 20) 
♦ Received  allocated intervention ( n = 15 )
♦ Did not re ceive allo cated  in tervention  (n = 5)  
(n = 1:  change in cli nical diagnosis:–  withdrawn;  
n = 1: large tumou r: con ver ted to ORC;  n = 3: 
LRC surgeon  unavail abilit y: co nverte d to RA RC)
♦ Lost  to follow -up at  90 d (n = 0) 
♦ Lost to follow -up at  12 mo (n = 1) 
♦ Disco ntinued in tervention ( n = 1)  (change in  
clinical diagnosis) 
Analy sed (n = 19) 
♦ Excl ude d from  all  analysis  (n = 1) due  to  cha nge 
in clin ical  diagno sis 
♦ Excl ude d from  analysis  of oncol ogic  outco mes at 
12 mo (n = 1) (lost  to follow-up at 12  mo) 
Fig. 1 – Consolidated Standards of Reporting Trials flow diagram.
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy.
Table 1 – Patient demographics
ORC (n = 20) RARC (n = 20) LRC (n = 19)
Age, yr, mean (SD) 66.6 (8.8) 68.6 (6.8) 68.6 (9.9)
BMI, kg/m2, mean (SD) 27.4 (3.9) 27.5 (4.2) 26.2 (3.6)
Male, n (%) 18 (90) 17 (85) 15 (79)
ASA grade, n (%)
ASA 1 4 (20) 4 (20) 3 (16)
ASA 2 15 (75) 15 (75) 13 (68)
ASA 3 1 (5) 1 (5) 3 (16)
ASA = American Society of Anesthesiologists; BMI = body mass index;
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy;
RARC = robot-assisted radical cystectomy; SD = standard deviation.
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3.3. Secondary end points
3.3.1. Perioperative outcomes
Mean operative time was significantly longer for RARC
compared with ORC (p < 0.001) and LRC (p < 0.001). Time
to solids was significantly longer for ORC compared with
RARC (p = 0.049) and LRC (p = 0.01). LOS was significantly
longer after ORC compared with LRC only (p = 0.005). There
were no statistically significant differences between surgi-
cal arms and time to flatus or EBL (Table 6).
3.3.2. Pathologic outcomes
Overall, 2 of 20 ORC patients (10%), 3 of 20 RARC patients
(15%), and 1 of 19 LRC patients (5%) had positive surgical
margins (PSMs). Of these, three had carcinoma in situ (CIS)
at the proximal urethral margin, and the other three had
bladder PSMs. There was no significant relationship
between surgical arm and PSMs.
Mean lymph node yield was 18.8 in the ORC group,
16.3 in the RARC group, and 15.5 in the LRC group. The
differences in lymph node yield between ORC and LRC were
statistically significant (p = 0.01).
3.4. Oncologic outcomes
At 12 mo, 10 patients had disease recurrence (ORC: 2 of 19,
RARC: 5 of 19, LRC: 3 of 18; p = 0.5) and 4 had died (ORC: 0 of
19, RARC: 1 of 20, LRC: 3 of 18; p = 0.1) including two from
BCa (ORC: 0 of 19, RARC: 0 of 20, LRC: 2 of 18; p = 0.1). One
ORC patient and one LRC patient were lost to follow-up.
Table 7 shows the details of recurrences. There were no
port-site metastases. There was no statistically significant
relationship between surgical arm and 12-mo oncologic
outcomes (recurrence, overall mortality, or disease-specific
mortality).
Figure 2 shows Kaplan-Meier survival estimates from
surgery to death or last follow-up. Figure 3 breaks this down
by surgical modality. The differences in survival were not
statistically significant (p = 0.7). Longer-term follow-up is
currently underway.
3.5. Quality-of-life measures
Overall, 53 patients completed the QoL questionnaire. One
questionnaire was analysed per patient (average 8 mo
postoperatively). Incomplete questionnaires were exclud-
ed. There were no statistically significant relationships in
QoL according to surgical arm (Table 8).
4. Discussion
The CORAL trial is the first randomised controlled trial
comparing ORC, RARC, and LRC. Although randomisation
was feasible, single-centre recruitment was slow. The best
means of recruitment is to contact patients directly while
maintaining clinical equipoise. Follow-up was achievable
with minimal attrition: 100% and 97% completed 90-d and
12-mo follow-up, respectively.
The 30-d complication rates (at least one complication)
were significantly different between the groups overall;
specifically, ORC patients had significantly more 30-d
complications compared with LRC. There was no difference
in 30-d major complications and all or major 90-d
complications. Although RARC was associated with longer
operative times compared with ORC and LRC, patients
Table 2 – Surgical factors
ORC
(n = 20)
RARC
(n = 20)
LRC
(n = 19)
Neoadjuvant chemotherapy 3 (15) 2 (10) 4 (21)
Preoperative diagnosis
NMIBC 8 (40) 8 (40) 5 (26)
MIBC 12 (60) 12 (60) 14 (74)
Diversion type
Ileal conduit 17 (85) 18 (90) 18 (95)
Neobladder 3 (15) 2 (10) 1 (5)
Final pathologic stage, mean
T0 4 2 3
Ta/T1/Tis 10 9 5
T2 0 3 3
T3 4 6 7
T4 2 0 1
LRC = laparoscopic radical cystectomy; MIBC = muscle-invasive bladder
cancer; NMIBC = non–muscle-invasive bladder cancer; ORC = open radical
cystectomy; RARC = robot-assisted radical cystectomy.
The data are presented as number (percentage) unless speciﬁed.
Table 3 – Primary outcome measures
ORC (n = 20) RARC (n = 20) LRC (n = 19) p value (95% CI for difference
where appropriate)
30-d complications (any grade)
At least one complication 14 (70) 11 (55) 5 (26) p = 0.024
Pairwise comparisons ORC vs RARC
RARC vs LRC
ORC vs LRC
15% (15 to 46; p = 0.5)
29% (58 to 0.8; p = 0.1)
44% (15–72; p = 0.01)
30-d major complications (at least Clavien 3)
At least one major complication 4 (20) 6 (30) 1 (5) p = 0.2
90-d complications (any grade)
At least one complication 14 (70) 11 (55) 6 (32) p = 0.068
90-d major complications (at least Clavien 3)
At least one major complication 4 (20) 7 (35) 2 (11) p = 0.2
CI = conﬁdence interval; LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy.
The data are presented as number (percentage) unless speciﬁed.
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undergoing ORC had a longer time to return to solids and
longer LOS compared with the minimally invasive
approaches. Significantly more lymph nodes were retrieved
in the ORC group compared with LRC but not RARC.
This study adds to the existing literature as the only
study with LRC as a separate arm in addition to ORC and
RARC. Inclusion of LRC was deemed logical at trial initiation
because RARC was not yet widely performed in the United
Kingdom, and it was believed that LRC could be a valuable
tool for institutions lacking the means to set up a robotic
program.
Three randomised trials have been published comparing
ORC with RARC, with strikingly similar results. RARC has
been shown to improve some perioperative parameters
such as EBL and LOS, but in all three studies no significant
differences were found in complication rates [6–8]. A recent
systematic review comparing RARC with ORC similarly
concluded that although RARC can be performed safely,
complication rates remain significant [18].
In terms of primary outcomes, although the only
statistically significant difference was in 30-d complica-
tions between ORC and LRC, we found an unexpected
overall trend toward reduced complication rates for LRC.
Although a surgeon bias could have influenced the results,
we have minimised this by ensuring that all surgeons in the
trial were well over their learning curve for cystectomy. In
addition, study arms were well matched (Tables 1 and 2).
Compared with previously published LRC outcomes, LRC
complication rates reported in this study were particularly
good, which could have resulted from the small numbers in
each arm because the target sample size could not be met
due to early trial termination. For example, a recent
multicentre study including data from the LRC surgeon in
this trial reported an LRC complication rate of 54% [19] that
is considerably higher than our findings (26% and 32% at
30 and 90 d, respectively). Ultimately, LRC remains a
technically challenging procedure, and it also lacks the
ergonomic advantage offered by RARC [20]. Our findings are
insufficient to recommend LRC over RARC, but they do
suggest that in expert hands, LRC could achieve good
results.
We reported PSM rates of 10%, 15%, and 5%, respectively,
for ORC, RARC, and LRC. The rate for RARC seems high,
especially considering the Pasadena Consensus Panel
recommendation of <7% PSM rate for RARC [21]. However,
we believe our findings reflect our practice of not routinely
performing simultaneous urethrectomy unless there is
tumour in the urethra because this increases morbidity.
Table 4 – Complications classified by Clavien grade
Clavien
grade
30 d 90 d
ORC RARC LRC p value ORC RARC LRC p value
1 8 3 1 0.030 0 0 0 –
2 5 10 6 0.3 2 2 1 >0.9
3 4 3 1 0.5 2 2 1 >0.9
4 0 2 0 0.3 0 2 0 0.3
5 0 0 0 – 0 0 0 –
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy;
RARC = robot-assisted radical cystectomy.
Note: Some patients had more than one complication.
Table 5 – Complications classified by system
ORC RARC LRC
0–30 d 30–90 d 0–30 d 30–90 d 0–30 d 30–90 d
Infectious (n = 27)
Intra-abdominal collection 4 2 1 0 1 0
Urosepsis 2 1 5 2 4 1
Balanitis 0 1 0 0 0 0
Pneumonia 0 0 2 0 1 0
Gastrointestinal (n = 12)
Ileus 7 0 1 0 0 0
Rectal injury 1 0 0 0 0 0
Anastomotic bowel leak 0 0 1 0 0 0
Small bowel obstruction 0 0 1 0 0 0
Small bowel ﬁstula 0 0 0 0 0 1
Genitourinary (n = 11)
Urine leak 3 0 1 1 0 0
Ureteric stricture/hydronephrosis
requiring drainage
0 0 1 1 0 0
Acute kidney injury 0 0 1 1 2 0
Thromboembolic (n = 1)
Pulmonary embolism 0 0 1 0 0 0
Cardiac (n = 1)
Myocardial infarction 0 0 0 1 0 0
Bleeding (n = 1)
Postoperative bleeding 0 0 1 0 0 0
Neurologic (n = 1)
Acute confusional state 1 0 0 0 0 0
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy.
Note: Some patients had more than one complication.
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Instead, patients with positive urethral margins undergo
interval urethrectomy, and this practice has not affected our
long-term oncologic outcomes. The three patients in this
series who only had CIS at the urethral margin underwent
interval urethrectomy with no residual disease.
The 12-mo oncologic outcomes measured by disease
recurrence and disease-specific mortality were equivalent
between arms. A recent study showed similar oncologic
outcomes between RARC and ORC at 5 yr of follow-up [22],
in agreement with the Pasadena Consensus Panel [20]. The
evidence thus far suggests that oncologic outcomes reflect
tumour biology, and technology is unlikely to have a
significant influence [23].
Few studies have reported on the impact of surgical
modality on QoL after RC. One recently published study
measured QoL using the Functional Assessment of Cancer
Therapy–Vanderbilt Cystectomy Index questionnaire and
found no difference between ORC and RARC [24]. We used
the validated FACT-Bl questionnaire with similar results.
This study has a few limitations. First, initial power
calculations were based on our early published data
[12]. With increasing experience and cumulative evidence,
it is now clear that a 10–15% RARC complication rate is a
significant underestimation, and consequently so is our
calculated target sample size.
Second, although single-centre recruitment reduces
variability in care, it resulted in slow progress and failure
to achieve our target sample size. Recruitment difficulties in
surgical trials are well recognised [25,26]. Surgical technol-
ogy evolves rapidly, and perpetual technique modifications
Table 6 – Secondary outcome measures
ORC (n = 20) RARC (n = 20) LRC (n = 19)
Perioperative outcomes
Operative time, min, mean (SD) 293 (66) 389 (98) 301 (51) p < 0.001
ORC vs RARC
RARC vs LRC
ORC vs LRC
95.5 (149 to 42; p < 0.001)
87.7 (34–142; p < 0.001)
7.8 (62 to 46; p = 0.9)
Estimated blood loss, ml, mean (SD) 808 (329) 585 (618) 460 (485) p = 0.070
Time to ﬂatus, d, mean (SD) 3.7 (1.6) 3.6 (2.5) 2.9 (1.1) p = 0.3
Time to oral solids, d*, mean (SD) 7.5 (5.7) 4.0 (4.0) 4.0 (4.4) p = 0.030
Mann-Whitney U test ORC vs RARC
RARC vs LRC
ORC vs LRC
3.5 (0.75–4.25; p = 0.049)
0.0 (0.25 to 0.25; p = 0.5)
3.5 (1.0–4.0; p = 0.01)
Length of stay, d, mean (SD) 14.4 (5.9) 11.9 (6.2) 9.7 (3.6) p = 0.031
ORC vs RARC
RARC vs LRC
ORC vs LRC
2.45 (1.40 to 6.30; p = 0.3)
2.16 (1.73 to 6.06; p = 0.4)
4.61 (0.72–8.51; p = 0.005)
Pathologic outcomes, n/n (%)
Positive resection margins 2/20 (10) 3/20 (15) 1/19 (5) p = 0.9
Oncologic outcomes at 12 mo**, n/n (%)
Recurrence 2/19 (11) 5/19 (26) 3/18 (17) p = 0.5
Overall mortality 0/19 (0) 1/20 (5) 3/18 (17) p = 0.1
Disease-speciﬁc mortality 0/19 (0) 0/20 (0) 2/18 (11) p = 0.1
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy.
* Time to oral solids, d: data presented with median and interquartile range.
** 12-mo recurrence: n = 2 were lost to follow-up, n = 1 died before 12 months therefore not analysed for 12-month recurrence. 12-mo overall mortality: 2
participants were lost to follow-up; 12-mo disease-speciﬁc mortality: 2 participants were lost to follow-up and 2 died from other disease but were still included
in the analysis.
Table 7 – Details of patients with recurrences
Surgical arm Type of
recurrence
Final
pathology
Margin
status
Management after recurrence Status at last
follow-up
ORC Distant pT3aN2 Negative Adjuvant CT followed by palliative RT Died (DS) at 18 mo
ORC Local pT1N2 Negative Declined adjuvant CT, subsequently
received palliative CT and RT
Died (DS) at 2 yr
RARC Nodal pT3cN0 Positive
(urethral)
RT to pelvic nodes Alive at 4 yr
RARC Distant and nodal pT2bN0 Negative Palliative CT Died (DS) at 18 mo
RARC Distant pTisN0 Negative Palliative symptomatic management Died (DS) at 3 yr
RARC Distant pT2N0 Negative Palliative RT Alive at 2 yr
RARC Nodal pT2bN2 Negative Palliative CT Died (DS) at 18 mo
LRC Distant pT3bN1 Negative CT Died (DS) at 6 mo
LRC Distant and nodal pT3bN0 Negative Palliative RT Died (DS) at 4 yr
LRC Local pT3bNx Negative Palliative symptomatic management Died (DS) at 6 mo
CT = chemotherapy; DS = disease speciﬁc; LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy; RARC = robot-assisted radical cystectomy;
RT = radiotherapy.
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can confound trials running over many years [27]. This
consideration, coupled with our interim analysis suggesting
no significant difference in primary outcomes between the
arms, informed our decision to terminate the trial after 3 yr.
One problem with recruitment was that a significant
number of patients declined randomisation because they
preferred the robotic approach. Despite this, 65% of eligible
patients did participate, showing that randomisation into
surgical trials is feasible provided that patients are well
counselled.
Third, as previously mentioned, each surgical modality
was carried out by a different surgeon, which can
potentially introduce surgeon bias. We are confident that
this bias was minimised to the best of our ability because, as
stated earlier, all three surgeons were well over their
learning curves for their respective operative modality, but
this point does lend caution to our outcomes, and we would
recommend further trials of this nature be carried out in
multiple centres with multiple surgeons.
Fourth, there was significant crossover between arms,
especially between LRC and RARC due to the LRC surgeon
being unavailable due to emergencies at his base hospital at
short notice. However, it was thought inappropriate to
delay the operation for this reason, and therefore patients
proceeded with their operation but using a different
modality than their original assignment. To reduce bias,
analysis was performed by intention to treat.
Lastly, the proportion of patients within our cohort who
had an orthotopic neobladder may be considered low at
10%. However, this figure is representative of our practice
and also of UK patients in general [28]. Also, all urinary
diversions were performed extracorporeally, which was
standard of care when the trial was conceived. RARC is
increasingly performed intracorporeally, and future studies
should take this into consideration.
Professor Studer commented at the 2015 European
Association of Urology congress that while RARC is feasible,
there is yet insufficient evidence to consider it the gold
standard [29]. The findings of the CORAL trial support this
statement, and we recommend a multicentre trial such as
the ongoing RAZOR trial [30] in the United States to further
evaluate this technique.
5. Conclusions
This is the first randomised controlled trial comparing ORC,
RARC, and LRC. The 30-d complication rates varied
significantly by surgical modality and were significantly
greater for ORC compared with LRC. There were no
significant differences in 30-d complication rates between
RARC and either ORC or LRC. There were no significant
differences in 90-d complication rates.
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Fig. 3 – Kaplan-Meier survival estimate for days from surgery to death or
last follow-up by surgical arm (p = 0.72).
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy;
RARC = robot-assisted radical cystectomy.
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Fig. 2 – Kaplan-Meier survival estimate for days from surgery to death or
last follow-up for all patients.
Table 8 – Quality-of-life analysis
QoL variable ORC, n = 16,
mean (SD)
RARC, n = 15,
mean (SD)
LRC, n = 15,
mean (SD)
FACT-Bl*
total score,
0–152
124.9 (12.7) 122.3 (17.1) 127.4 (13.5) p = 0.6
FACT-G** total
score, 0–108
90.0 (9.9) 87.9 (14.6) 92.9 (12.0) p = 0.5
TOI, 0–104*** 80.3 (11.7) 78.8 (12.2) 81.7 (9.0) p = 0.8
BlCS = Bladder Cancer Subscale; EWB = emotional well-being; FACET-
G = Functional Assessment of Cancer-General; FACT-B1 = Functional
Assessment of Cancer Therapy-Bladder; FWB = functional well-being;
LRC = laparoscopic radical cystectomy; ORC = open radical cystectomy;
PWB = physical well-being; QoL = quality of life; RARC = robot-assisted
radical cystectomy; SD = standard deviation; SWB = social/family well-
being; TOI = Trial Outcome Index.
* FACT-Bl score = PWB, SWB, EWB, FWB, and BlCS.
** FACT-G score = PWB, SWB, EWB, and FWB.
*** TOI score = PWB, FWB, and BlCS.
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